VolitionRX Ltd (VNRX) Stock Analysis
Verdict: AVOID
Strong Nu.Q product revenue growth (+112%) cannot mitigate severe insolvency risk from a <1 month cash runway ($1.1M vs $19.7M burn).
Investment score: 16/100
Analysis as of
Is VolitionRX Ltd stock worth reviewing? AI model thesis
The AI model assigns an AVOID recommendation due to acute liquidity distress (<1 month cash runway) and chronic EPS misses, despite top-line revenue growth in Nu.Q diagnostics platforms.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
VolitionRX Ltd opportunities and risks
What speaks for VNRX
- Nu.Q diagnostic platform adoption expanding rapidly
What speaks against VNRX
- Immediate liquidity crisis and severe shareholder dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VNRX | n/a | 1.5x | n/a | 89.6% | -1043.1% | -525.7% |
| NSPR | n/a | 3.8x | n/a | 18.1% | -355.2% | -102.7% |
| RMTI | n/a | 0.5x | n/a | 17.7% | -7.3% | 4.9% |
| TELA | n/a | 0.4x | n/a | 67.8% | -51.5% | -105.5% |
| RVP | n/a | 0.6x | 4.4x | 1.1% | -9.9% | -23.3% |
| ADVB | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.1% |
| Peer median | n/a | 0.5x | n/a | 17.7% | -9.9% | -23.3% |
Frequently asked questions about VolitionRX Ltd (VNRX)
Is VNRX stock a good investment?
The cached TradeMates AI model rates VolitionRX Ltd as AVOID with an investment score of 16/100. The AI model assigns an AVOID recommendation due to acute liquidity distress (<1 month cash runway) and chronic EPS misses, despite top-line revenue growth in Nu.Q diagnostics platforms. This is algorithmic model output, not personal investment advice.
Is VNRX stock a buy?
The TradeMates model verdict for VNRX is AVOID with an investment score of 16/100. Treat this as a model signal to review, not a personal buy recommendation.